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Prostate cancer is the second most frequently diagnosed
cancer in men worldwide and sixth leading cancer-related
cause of death in males. Treatments for recurrent prostate
cancer are only rarely curative, and the majority of patients
eventually demonstrate progressive disease. Animal and
clinical studies suggested that immunological approaches
can be useful for prostate cancer treatment and preven-
tion. The development of immunotherapy for prostate
cancer based on the induction of autoimmunity to
prostate-specific differentiation antigens is an attractive
concept. Prostate specific antigen (PSA) is a serine
protease of the glandular kallikrein gene family with highly
restricted expression on prostate tumor cells and normal
prostate. Previous attempts to develop PSA-based vaccines
for prostate cancer primarily using poxvirus and adeno-
virus vectors resulted in promising clinical and immune
responses. However, these approaches had limitations due
to pre-existing antibody responses to viral vectors and
insufficient safety. Previously we have constructed novel
non-replicative alphavirus vector platform derived from
live attenuated human TC-83 IND vaccine against Vene-
zuelan equine encephalitis (VEE) virus infection. In earlier
studies, vaccines based on alphaviruses demonstrated
efficiency in targeted gene delivery to DC and induction of
protective CTL immunity against several human viral
pathogens and breast cancer in a rodent animal model. In
this study we tested novel TC-83 based PSA-encoding
alphavirus vaccine (vVLP-PSA) against prostate cancer
using transgenic mouse model with established neonatal
tolerance to human PSA. Preventive vaccination using
vVLP-PSA demonstrated induction of strong PSA-specific
CD8+ T-cell response as detected by IFNg ELISPOT assay
and intracellular cytokine staining. Potent expansion
of PSA-specific CD8+ effector T-cells was found in
peripheral blood and spleens of vaccinated mice using
PSA peptide-loaded MHC I dextramers. vVLP-PSA vacci-
nation also induced PSA-specific antibody production
in immunized mice. Injection of TRAMP tumor cells
expressing PSA into vaccinated mice resulted in elevated
infiltration of tumor site with CD8+ T-cells and rapid
elimination of PSA-expressing tumor cells during first
several weeks after tumor challenge. Tumor survival analy-
sis revealed tendency for delayed tumor growth in vVLP-
PSA immunized mice. Altogether, our data demonstrate
that TC83-based vaccine encoding PSA induces strong
PSA-specific CTL response and mediates efficient elimina-
tion of antigen-expressing prostate tumor cells promptly
after tumor challenge.
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